Diabetic Polyneuropathy Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of RWJ 333369 for the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy.
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of 200 mg of RWJ-333369 given twice daily by mouth compared with placebo in the treatment of Diabetic Peripheral Neuropathy (DPN).
Diabetes mellitus is the most common cause of neuropathy in the Western World, with up to 50% of patients developing neuropathy as a long-term complication of the illness, of whom 10% experience pain. Diabetic neuropathy most often affects the lower extremities and may be severe if inadequately treated. Blood glucose control is a critical treatment element, and several medications have been demonstrated to be effective in treating Diabetic Peripheral Neuropathy (DPN), including antiepileptic drugs, antidepressants and opioid analgesics. These medications are often limited by incomplete pain relief and side effects. This is a randomized (study medication is assigned by chance), double-blind (neither the Investigator or the patient know the name of the assigned study medication), placebo-controlled, crossover, parallel-group, multicenter study to determine the effectiveness and safety of 200 mg of RWJ-333369 given twice daily by mouth for 4 weeks compared with placebo in patients with DPN. The study hypothesis is that 200 mg of RWJ-333369 given twice daily by mouth for 4 weeks will be more effective than placebo in reducing pain due to DPN, as measured by average daily DPN pain scores. Patients will receive 200 mg of RWJ-333369 or matching placebo tablets, given in equally divided doses twice daily by mouth with or without food, for 4 weeks in each of the 2 treatment periods. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06040567 -
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
|
||
Completed |
NCT02423434 -
Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
|
||
Completed |
NCT05542901 -
Comparison of Joint Position Sense in Diabetic and Traumatic Transtibial Amputees
|
N/A | |
Withdrawn |
NCT01536236 -
Spinal Cord Stimulation for Diabetic Polyneuropathy
|
N/A | |
Active, not recruiting |
NCT01175928 -
Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy
|
Phase 1/Phase 2 | |
Completed |
NCT00993070 -
Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT00539175 -
Treatment of Painful Diabetic Neuropathy With Photon Stimulation
|
N/A | |
Completed |
NCT00278980 -
Effect of C-Peptide on Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT04593992 -
HTEMS Treatment of Diabetic Polyneuropathy
|
N/A | |
Completed |
NCT01465620 -
Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study
|
Phase 3 | |
Completed |
NCT01079325 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00406458 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Recruiting |
NCT06072573 -
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
|
Phase 3 | |
Recruiting |
NCT06071975 -
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
|
Phase 3 | |
Recruiting |
NCT05521737 -
Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01847937 -
Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT00476931 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00977483 -
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)
|
Phase 3 | |
Completed |
NCT01006915 -
Surgical Decompression for Diabetic Neuropathy in the Foot
|
N/A | |
Completed |
NCT00307749 -
Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy
|
Phase 2 |